We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $3.89B
1-Year Est. Return 201.1%
This Fund
S&P 500
This Quarter Est. Return
+49.94%
1 Year Est. Return
+201.1%
3 Year Est. Return
+879.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.34B
AUM Growth
+$837M
Cap. Flow
-$3.86M
Cap. Flow %
-0.12%
Top 10 Hldgs %
69.46%
Holding
53
New
4
Increased
10
Reduced
7
Closed
6

Top Buys

1
ABVX
Abivax
ABVX
+$23.2M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$14.5M
3
CYTK icon
Cytokinetics
CYTK
+$13.8M
4
DYN icon
Dyne Therapeutics
DYN
+$13.8M
5
ZLAB icon
Zai Lab
ZLAB
+$11M

Top Sells

1
HLVX
HilleVax
HLVX
+$21.1M
2
CGON icon
CG Oncology
CGON
+$20M
3
IRON icon
Disc Medicine
IRON
+$12.9M
4
COGT icon
Cogent Biosciences
COGT
+$12.5M
5
TVTX icon
Travere Therapeutics
TVTX
+$11.5M

Sector Composition

1 Healthcare 99.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HLVX
51
DELISTED
HilleVax
HLVX
– –
-10,617,062
Closed -$21.1M
ORIC icon
52
Oric Pharmaceuticals
ORIC
$1.13B
– –
-1,065,334
Closed -$10.8M
ORKA
53
Oruka Therapeutics
ORKA
$5.44B
– –
-583,327
Closed -$6.54M
1 2
3

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $3.88B AUM 23.82% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
CCM
Channing Capital Management Chicago, Illinois $3.91B AUM 34.32% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
AA
Alesco Advisors Pittsford, New York $3.92B AUM 15.21% 1-Year Est. Return
DACG
Donor Advised Charitable Giving San Francisco, California $3.92B AUM 59.92% 1-Year Est. Return

Frazier Life Sciences Management's Q3 2025 Portfolio in Review

As of Q3 2025, Frazier Life Sciences Management held 53 positions worth $3.34B, up 33% from $2.5B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Frazier Life Sciences Management's Q3 2025 filing shows 4 new, 10 increased, 7 reduced and 6 closed positions. Its largest new stake was Abivax: 378,300 shares worth $32.1M. The largest sale was HilleVax, an estimated $21.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

  • Frazier Life Sciences Management's largest Q3 2025 buy was Abivax: 378,300 shares worth $32.1M.
  • Frazier Life Sciences Management added most to Cytokinetics in Q3 2025, an estimated $13.8M increase.
  • Frazier Life Sciences Management's biggest Q3 2025 reduction was Disc Medicine, cutting an estimated $12.9M.
  • Frazier Life Sciences Management fully exited HilleVax in Q3 2025, selling an estimated $21.1M.
  • Frazier Life Sciences Management's ten largest holdings make up 69% of its $3.34B portfolio in Q3 2025.
  • Frazier Life Sciences Management opened 4 new positions and closed 6 in Q3 2025.
  • Frazier Life Sciences Management's portfolio value rose 33% quarter-over-quarter to $3.34B.

Based on Frazier Life Sciences Management's 13F filing for Q3 2025, filed 14 Nov 2025.